Copyright Reports & Markets. All rights reserved.

Global Polycystic Ovary Syndrome (PCOS) Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Polycystic Ovary Syndrome (PCOS) Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size Growth Rate by Product
      • 1.4.2 Oral Contraceptives
      • 1.4.3 Antiandrogens
      • 1.4.4 Insulin-sensitizing Agent
      • 1.4.5 Antidepressant
      • 1.4.6 Anti-obesity
    • 1.5 Market by End User
      • 1.5.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size
      • 2.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue 2014-2025
      • 2.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales 2014-2025
    • 2.2 Polycystic Ovary Syndrome (PCOS) Drugs Growth Rate by Regions
      • 2.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Regions
      • 2.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Polycystic Ovary Syndrome (PCOS) Drugs Sales by Manufacturers
      • 3.1.1 Polycystic Ovary Syndrome (PCOS) Drugs Sales by Manufacturers
      • 3.1.2 Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Manufacturers
      • 3.2.1 Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Polycystic Ovary Syndrome (PCOS) Drugs Price by Manufacturers
    • 3.4 Polycystic Ovary Syndrome (PCOS) Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Polycystic Ovary Syndrome (PCOS) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Polycystic Ovary Syndrome (PCOS) Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Polycystic Ovary Syndrome (PCOS) Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Product
    • 4.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Product
    • 4.3 Polycystic Ovary Syndrome (PCOS) Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Polycystic Ovary Syndrome (PCOS) Drugs by Countries
      • 6.1.1 North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Countries
      • 6.1.2 North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Polycystic Ovary Syndrome (PCOS) Drugs by Product
    • 6.3 North America Polycystic Ovary Syndrome (PCOS) Drugs by End User

    7 Europe

    • 7.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs by Countries
      • 7.1.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Countries
      • 7.1.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs by Product
    • 7.3 Europe Polycystic Ovary Syndrome (PCOS) Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs by Countries
      • 8.1.1 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Countries
      • 8.1.2 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs by Product
    • 8.3 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Polycystic Ovary Syndrome (PCOS) Drugs by Countries
      • 9.1.1 Central & South America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Countries
      • 9.1.2 Central & South America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Polycystic Ovary Syndrome (PCOS) Drugs by Product
    • 9.3 Central & South America Polycystic Ovary Syndrome (PCOS) Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs by Countries
      • 10.1.1 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs by Product
    • 10.3 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs by End User

    11 Company Profiles

    • 11.1 Sanofi
      • 11.1.1 Sanofi Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.1.5 Sanofi Recent Development
    • 11.2 Novartis AG
      • 11.2.1 Novartis AG Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.2.5 Novartis AG Recent Development
    • 11.3 Teva Pharmaceutical Industries Limited
      • 11.3.1 Teva Pharmaceutical Industries Limited Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.3.5 Teva Pharmaceutical Industries Limited Recent Development
    • 11.4 Addex Therapeutics Ltd.
      • 11.4.1 Addex Therapeutics Ltd. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.4.5 Addex Therapeutics Ltd. Recent Development
    • 11.5 BIOCAD
      • 11.5.1 BIOCAD Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.5.5 BIOCAD Recent Development
    • 11.6 Merck KGaA
      • 11.6.1 Merck KGaA Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.6.5 Merck KGaA Recent Development
    • 11.7 AstraZeneca plc.
      • 11.7.1 AstraZeneca plc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.7.5 AstraZeneca plc. Recent Development
    • 11.8 Bristol Myers Squibb Co.
      • 11.8.1 Bristol Myers Squibb Co. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.8.5 Bristol Myers Squibb Co. Recent Development
    • 11.9 Ferring Pharmaceuticals, Inc.
      • 11.9.1 Ferring Pharmaceuticals, Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.9.5 Ferring Pharmaceuticals, Inc. Recent Development
    • 11.10 Crinetics Pharmaceuticals, Inc.
      • 11.10.1 Crinetics Pharmaceuticals, Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Products Offered
      • 11.10.5 Crinetics Pharmaceuticals, Inc. Recent Development

    12 Future Forecast

    • 12.1 Polycystic Ovary Syndrome (PCOS) Drugs Market Forecast by Regions
      • 12.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Polycystic Ovary Syndrome (PCOS) Drugs Market Forecast by Product
      • 12.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Polycystic Ovary Syndrome (PCOS) Drugs Market Forecast by End User
    • 12.4 North America Polycystic Ovary Syndrome (PCOS) Drugs Forecast
    • 12.5 Europe Polycystic Ovary Syndrome (PCOS) Drugs Forecast
    • 12.6 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Forecast
    • 12.7 Central & South America Polycystic Ovary Syndrome (PCOS) Drugs Forecast
    • 12.8 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Polycystic Ovary Syndrome (PCOS) Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Polycystic Ovary Syndrome (PCOS) Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Polycystic Ovary Syndrome (PCOS) Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Polycystic Ovary Syndrome (PCOS) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Polycystic Ovary Syndrome (PCOS) Drugs in these regions.
      This research report categorizes the global Polycystic Ovary Syndrome (PCOS) Drugs market by top players/brands, region, type and end user. This report also studies the global Polycystic Ovary Syndrome (PCOS) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Sanofi
      Novartis AG
      Teva Pharmaceutical Industries Limited
      Addex Therapeutics Ltd.
      BIOCAD
      Merck KGaA
      AstraZeneca plc.
      Bristol Myers Squibb Co.
      Ferring Pharmaceuticals, Inc.
      Crinetics Pharmaceuticals, Inc.

      Market size by Product
      Oral Contraceptives
      Antiandrogens
      Insulin-sensitizing Agent
      Antidepressant
      Anti-obesity
      Market size by End User
      Hospital
      Clinic

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Polycystic Ovary Syndrome (PCOS) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Polycystic Ovary Syndrome (PCOS) Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Polycystic Ovary Syndrome (PCOS) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Polycystic Ovary Syndrome (PCOS) Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Polycystic Ovary Syndrome (PCOS) Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Polycystic Ovary Syndrome (PCOS) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now